Luke T Lavallée1, Rodney H Breau1, Dean Fergusson1, Carl van Walraven1. 1. Division of Urology (Lavallee), Department of Surgery, Ottawa Hospital Research Institute and Institute of Clinical Evaluative Sciences; Division of Urology (Breau), Department of Surgery, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute (Fergusson); and Department of Medicine (van Walraven), Ottawa Hospital Research Institute, Ottawa, Ont.
Abstract
BACKGROUND: Prostate cancer is a substantial public health concern; however, in recent years, national guidelines have recommended against prostate cancer screening. We sought to determine if prostate biopsy incidence has changed over time in Ontario. We hypothesized that there has been a decrease in the incidence of prostate biopsy in recent years. METHODS: This cohort study used population-based administrative databases from Ontario, Canada. We used a diagnostic code to identify if a patient received his first prostate biopsy between 1992 and 2012 (the last year for which records in the Ontario Cancer Registry were complete). Age-stratified and overall age-standardized incidences of prostate biopsy were determined. Changes over time in prostate biopsy incidence and the proportion of prostate biopsies that showed malignant disease were examined using negative binomial regression adjusting for patient age. RESULTS: We identified 231 266 Ontario men aged 40 years and older who received their first prostate biopsy between 1992 and 2014. Up to 2007, biopsy incidence increased in younger men, but decreased in older men. After 2007, biopsy incidence decreased in all age groups, with the age-standardized overall biopsy incidence dropping from 480 per 100 000 in 2007 to 250 per 100 000 in 2014. A total of 84 149 (39%) incident biopsies showed malignant disease. The proportion of biopsies classified as showing malignant disease increased during the study period, from 25.6% in 1992 to 49.2% in 2010, and then decreased in all age groups. INTERPRETATION: Previously increasing biopsy rates decreased significantly in recent years, suggesting that prostate cancer screening in Ontario may be changing.
BACKGROUND:Prostate cancer is a substantial public health concern; however, in recent years, national guidelines have recommended against prostate cancer screening. We sought to determine if prostate biopsy incidence has changed over time in Ontario. We hypothesized that there has been a decrease in the incidence of prostate biopsy in recent years. METHODS: This cohort study used population-based administrative databases from Ontario, Canada. We used a diagnostic code to identify if a patient received his first prostate biopsy between 1992 and 2012 (the last year for which records in the Ontario Cancer Registry were complete). Age-stratified and overall age-standardized incidences of prostate biopsy were determined. Changes over time in prostate biopsy incidence and the proportion of prostate biopsies that showed malignant disease were examined using negative binomial regression adjusting for patient age. RESULTS: We identified 231 266 Ontario men aged 40 years and older who received their first prostate biopsy between 1992 and 2014. Up to 2007, biopsy incidence increased in younger men, but decreased in older men. After 2007, biopsy incidence decreased in all age groups, with the age-standardized overall biopsy incidence dropping from 480 per 100 000 in 2007 to 250 per 100 000 in 2014. A total of 84 149 (39%) incident biopsies showed malignant disease. The proportion of biopsies classified as showing malignant disease increased during the study period, from 25.6% in 1992 to 49.2% in 2010, and then decreased in all age groups. INTERPRETATION: Previously increasing biopsy rates decreased significantly in recent years, suggesting that prostate cancer screening in Ontario may be changing.
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245
Authors: Bimal Bhindi; Muhammad Mamdani; Girish S Kulkarni; Antonio Finelli; Robert J Hamilton; John Trachtenberg; Alexandre R Zlotta; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Neil E Fleshner Journal: J Urol Date: 2014-12-03 Impact factor: 7.450
Authors: David H Howard; Florence K Tangka; Gery P Guy; Donatus U Ekwueme; Joseph Lipscomb Journal: Health Aff (Millwood) Date: 2013-03 Impact factor: 6.301
Authors: Joshua A Cohn; Chihsiung E Wang; Justin C Lakeman; Jonathan C Silverstein; Charles B Brendler; Kristian R Novakovic; Michael S McGuire; Brian T Helfand Journal: Urol Oncol Date: 2013-08-02 Impact factor: 3.498
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: Stefan Zechmann; Stefania Di Gangi; Vladimir Kaplan; Rahel Meier; Thomas Rosemann; Fabio Valeri; Oliver Senn Journal: PLoS One Date: 2019-06-13 Impact factor: 3.240